CD40 Stimulation Obviates Innate Sensors and Drives T Cell Immunity in Cancer  by Byrne, Katelyn T. & Vonderheide, Robert H.
ArticleCD40 Stimulation Obviates Innate Sensors and
Drives T Cell Immunity in CancerGraphical AbstractHighlightsd CD40 stimulation converts T-cell-deficient tumors to
immunologically replete sites
d CD40 mediates clonal T cell expansion with decreased
regulatory T cells
d Functional adaptive immune responses require both CD40
stimulation and chemotherapy
d Converted tumors undergo durable responses independently
of innate immune sensorsByrne & Vonderheide, 2016, Cell Reports 15, 2719–2732
June 21, 2016 ª 2016 The Author(s).
http://dx.doi.org/10.1016/j.celrep.2016.05.058Authors
Katelyn T. Byrne, Robert H. Vonderheide
Correspondence
rhv@exchange.upenn.edu
In Brief
Immunologically ‘‘cold’’ tumors lack
T cells and are hyporesponsive to
immunotherapies. Byrne and
Vonderheide show that CD40 stimulation,
with chemotherapy, converts a ‘‘cold’’
tumor to a site of T cell infiltration and
destruction with durable responses.
Functional immune responses are
independent of innate immune sensors
important in other settings.
Cell Reports
ArticleCD40 Stimulation Obviates Innate Sensors
and Drives T Cell Immunity in Cancer
Katelyn T. Byrne1 and Robert H. Vonderheide1,*
1Abramson Cancer Center and Department of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA
*Correspondence: rhv@exchange.upenn.edu
http://dx.doi.org/10.1016/j.celrep.2016.05.058SUMMARY
Cancer immunotherapies are more effective in tu-
mors with robust T cell infiltrates, but mechanisms
to convert T cell-devoid tumors with active immuno-
suppression to those capable of recruiting T cells
remain incompletely understood. Here, using genet-
ically engineered mouse models of pancreatic ductal
adenocarcinoma (PDA), we demonstrate that a single
dose of agonistic CD40 antibody with chemo-
therapy rendered PDA susceptible to T cell-depen-
dent destruction and potentiated durable remis-
sions. CD40 stimulation caused a clonal expansion
of T cells in the tumor, but the addition of chemo-
therapy optimizedmyeloid activation and T cell func-
tion. Although recent data highlight the requirement
for innate sensors in cancer immunity, these canoni-
cal pathways—including TLRs, inflammasome, and
type I interferon/STING—played no role in mediating
the efficacy of CD40 and chemotherapy. Thus, CD40
functions as a non-redundant mechanism to convert
the tumor microenvironment immunologically. Our
data provide a rationale for a newly initiated clinical
trial of CD40 and chemotherapy in PDA.
INTRODUCTION
Innate immune cells utilize a number of receptors to detect
danger signals liberated when large numbers of host cells die,
such as after chemotherapy or radiotherapy in patients with can-
cer (Green et al., 2009). Dying tumor cells release intracellular
components such as high-mobility-group box 1, ATP, and
DNA, which are recognized, in turn, by receptors such as Toll-
like receptor (TLR) 4 (Apetoh et al., 2007), P2X7 receptor
(P2X7R) (Ghiringhelli et al., 2009), and stimulator of interferon
genes (STING) (Deng et al., 2014) to regulate immune responses
against tumors. Accordingly, a number of innate sensor agonists
are being brought forward for investigation in cancer patients
(Corrales and Gajewski, 2015; Kaczanowska et al., 2013; Rook
et al., 2015).
It is well-known that some chemotherapies can enhance anti-
tumor immunity, working most effectively in immunocompetent
versus deficient hosts (Emens and Middleton, 2015; Zitvogel
et al., 2008); however, some tumors, such as pancreatic ductalCell
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therapy and despite aggressive treatment, the 5-year survival
rate for patients with metastatic PDA is less than 5%. Immuno-
logically, PDA is uncommonly infiltrated by effector T cells and
expresses a relatively low burden of non-synonymous mutations
that could serve as neo-epitopes (Alexandrov et al., 2013; Jones
et al., 2008; Sausen et al., 2015), consistent with what has been
termed an immunologically ‘‘cold’’ tumor (Sharma and Allison,
2015). Newer combinations of chemotherapy, such as gemcita-
bine (Gem) and nab-paclitaxel (nP), have shown clinical promise
in metastatic PDA (garnering FDA approval in 2013), but objec-
tive tumor response rates remain low (23% of patients respond
to Gem/nP, compared to 7% with Gem alone) (Von Hoff et al.,
2013). Multiple hypotheses have been proposed to explain
how nP improves responses against PDA, including SPARC-
dependent (Alvarez et al., 2013; Von Hoff et al., 2011) or -inde-
pendent (Neesse et al., 2014) mechanisms of stromal destruc-
tion, decreased levels of cytidine deaminase (Frese et al.,
2012), andmacropinocytosis by KRASmutant tumor cells (Com-
misso et al., 2013). Although paclitaxel may activate macro-
phages as a lipopolysaccharide (LPS) mimetic that binds TLR4
(Ding et al., 1993)—which raises the hypothesis of an immune ef-
fect from adding nP—progression-free survival is extended by
only 1.8 months with Gem/nP compared to Gem alone (Von
Hoff et al., 2013) and without durable remissions in this disease.
To investigate immune mechanisms that could convert PDA
tumors from T cell-devoid to T cell-replete—as a first step to-
ward establishing immune sensitivity—we used the genetically
engineered KrasLSL-G12D/+,Trp53LSL-R172H/+, Pdx1-Cre (KPC)
mouse model of PDA, in which oncogenic KrasG12D and mutant
p53R172H are under the control of Cre recombinase specifically
expressed in the pancreas. KPC mice develop spontaneous
PDAwith 100%penetrance and faithful recapitulation of key fea-
tures of human disease (Hingorani et al., 2005), including a
dearth of non-synonymous mutations (similar to other KRAS-
induced mouse models of cancer; Westcott et al., 2015) and
minimal effector T cell infiltration (Clark et al., 2007). Although
CD40 ligation enhances immune activation andmaturation of an-
tigen presenting cells (APCs) (Bennett et al., 1998; Ridge et al.,
1998; Schoenberger et al., 1998), in tumor-bearing KPC mice,
aCD40 alone achieves only transient tumor regressions on the
basis ofmacrophage reeducation and not T cell immunity (Beatty
et al., 2011). Because aCD40 combined with vaccines drives
cytotoxic CD8+ T cell responses in the context of cancer (Diehl
et al., 1999; French et al., 1999; Sotomayor et al., 1999), we
explored aCD40 combined with chemotherapy as an in vivoReports 15, 2719–2732, June 21, 2016 ª 2016 The Author(s). 2719
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vaccine (Nowak et al., 2003) against PDA. The inability of aCD40
(with or without Gem) to generate potent T cell mediated regres-
sions of KPC tumors is mitigated upon the depletion of suppres-
sive macrophage populations (Beatty et al., 2015). We hypothe-
sized that adding nP to aCD40/Gem, taking advantage of
potential immune stimulating effects of paclitaxel (Ding et al.,
1993), might reeducate the suppressive macrophages and pro-
mote robust anti-tumor T cell immunity, bypassing the need for
macrophage depletion in this system.
Here, we report that aCD40 and the combination of Gem/nP—
but neither aCD40 nor chemotherapy alone—achieves T cell-
dependent regression of established tumors in mice, an effect
that requires IFN-g and host CD40. Tumor regression was
notably independent of multiple innate sensing pathways that
have been classically described as mediating both spontaneous
and therapy-induced cancer immunity. These preclinical data
provide themechanistic rationale for a newly initiated clinical trial
of Gem/nP/CD40 therapy in patients with PDA (http://www.
clinicaltrials.gov, #NCT02588443).
RESULTS
Chemotherapy Requires the Addition of aCD40
for Regression and Cure of Established PDA in a
T Cell-Dependent Manner
We harvested a spontaneous PDA tumor from a C57BL/6 KPC
mouse and generated a cell line (4662) with mutant KRAS and
P53 that grew progressively upon subcutaneous implantation
in wild-type syngeneic hosts with extensive desmoplastic
stroma in the tumor microenvironment (TME) (Lo et al., 2015).
Treatment of established 4662 tumors on day 12 with aCD40
and Gem/nP achieved significant regressions 12–14 days later
(median regression rate across experiments, 59.7% ± 26.0%),
whereas only rare regressions were observed in mice treated
with Gem/nP or aCD40 alone (Figure 1A). Additionally, the overall
tumor growth rate was significantly reduced in Gem/nP/aCD40
treated mice compared to mice treated with Gem/nP or aCD40
alone (Figure 1B). Similar results were found with a second des-
moplastic PDA cell line (G43) also derived from a C57BL/6 KPC
mouse (Figure S1). Gem/nP/aCD40 treated mice had signifi-
cantly enhanced overall survival, with 14.7% (versus 0%) of
mice being cured (Figure 1C). A second dose of Gem/nP
7 days later (day 19), to mimic the weekly dosing schedule in
the clinic (Beatty et al., 2013; Von Hoff et al., 2013), neither
enhanced nor hindered the rate of regression (Figure S2). Mice
that were cured of the primary tumor with Gem/nP/aCD40 treat-
ment rejected both 4662 and G43 tumor cells when injected
60 days or more later (Figure 1D and data not shown). This effect
reflected T cell-mediated memory against PDA, as mice cured
with Gem/nP/aCD40 and then depleted of CD8+ T cells after
60 days quickly succumbed to tumor if rechallenged (Figure 1D).
Depletion of either CD4+ or CD8+ T cells, or both, before initial
treatment with Gem/nP/aCD40 also abrogated the response to
therapy (Figure 1E). Thus, in contrast to the macrophage-depen-
dent response generated with aCD40 monotherapy, the combi-
nation of both Gem/nP and aCD40, but neither alone, effectively
mediated T cell-dependent regressions of PDA, reducing overall
tumor growth and enabling long-term cures.2720 Cell Reports 15, 2719–2732, June 21, 2016Gem/nP/aCD40 Therapy Skews the PDA
Microenvironment in Favor of Effector T Cells
Given that T cells mediated tumor regressions prominently on
day 23–25, we investigated CD4+ and CD8+ T cell subsets in
the TME at this time point. The prevalence of effector T cells
was similar or slightly increased with Gem/nP/aCD40 compared
to Gem/nP or aCD40 alone (Figure 2A), but FoxP3+ T regulatory
cells (TRegs), comprising nearly 20% of total CD3
+ T cells
in vehicle or Gem/nP treated mice (data not shown), was
significantly reduced after treatment with aCD40 and nearly
completely eliminated with the addition of Gem, nP, or both (Fig-
ure 2B). As a result, the effector T cell:TReg ratios were signifi-
cantly skewed in favor of both CD4+ and CD8+ effector T cells
in the TME after aCD40 (Figure 2C), independently of the addition
of Gem and/or nP. The significant reduction in TRegs after aCD40
therapywas observed in both the proportions and in the absolute
number of T cell subsets (Figure 2C and data not shown). CD4+
T cell subsets in the TME were significantly altered as early as
5 days after aCD40, when the proportions of FoxP3+ and
GATA3+ CD4+ T cells were significantly reduced in Gem/nP/
aCD40 treated mice, concurrent with an increase in RORgt+
and Tbet+ CD4+ cells (Figure 2D).
aCD40 Therapy Increases the Clonal T Cell Response
against PDA
To further investigate the effects of aCD40 on the T cell reper-
toire, we performed T cell receptor (TCR)-b chain CDR3 region
deep sequencing to track unique T cell clones in tumors har-
vested from mice treated with Gem/nP/aCD40, aCD40 alone,
Gem/nP alone, or vehicle control. To differentiate the effect of
each therapy on the TCR repertoire, mice were grouped by
aCD40 treatment (Figures 2E and 2F, top) or Gem/nP treatment
(bottom) and analyzed by machine learning using random forest
classification (RFC), as we have previously reported (Twyman-
Saint Victor et al., 2015). This unbiased analysis approach suc-
cessfully segregated mice based on aCD40 therapy, regardless
of Gem/nP treatment, indicative of the impact of CD40 stimula-
tion (but not chemotherapy) on clonal T cell responses in the
TME. Among all mice that received aCD40, the cumulative pro-
portions of rare and small clones (those found at a frequencies
<0.01%) were significantly increased and hyperexpanded
clones (highly represented clones in the TME) were moderately
increased, compared to mice that did not receive aCD40 (Fig-
ure 2E, top). In comparison, the cumulative frequencies of rare
to hyperexpanded clones remained constant when mice were
segregated by chemotherapy treatment only, regardless of
CD40 treatment (Figure 2E, bottom). The moderate increase of
hyperexpanded clones in aCD40 treated mice significantly
impacted the diversity of the most prevalent clones within the
TME, such that the true diversity (measuring the effective num-
ber of clones) was increased for the top 10 and 20 clones within
the TME, but not for the entire T cell population (Figure 2F, top).
Thus theGini coefficient (clonality) was significantly increased for
the entire response after aCD40 therapy (Figure 2F, top), reflect-
ing the expansion of the most frequent clones in the TME. Again,
only exposure to aCD40 and not chemotherapy impacted these
diversity and clonal metrics (Figure 2F, bottom). Furthermore,
these changes were only observed in the TME itself; using the
Figure 1. Gem/nP/aCD40 Drives T Cell-Dependent Regressions of PDA
Mice were injected with PDA 4662 cells subcutaneously and, after 12 days of growth, tumors were treated with Gem/nP followed by aCD40 2 days later.
(A) Left, change in tumor volume on day 24 compared to start of treatment (day 12), representative of seven independent experiments. Right, the total proportion
of regressors/experiment, from 13 individual experiments, with the total number of mice/group shown below.
(B) Tumor growth kinetics for mice from (A).
(C) Survival curve for mice treated as described in (A), from two combined experiments.
(D) Survival after second tumor injection >60 days after primary tumor injection. Some mice received aCD8, representative of two independent experiments.
(E) Mice were treated as described in (A), and with aCD4 and/or aCD8. On the left, the change in tumor growth compared to baseline is shown, and, on the right,
tumor growth kinetics are shown. The data are representative of three independent experiments.
Each experiment had 4–10 mice/group, each bar represents a single mouse, and each symbol represents a group, the horizontal line and error bars indicate
mean ± SEM. The statistical analyses by one-way ANOVA (A), two-way ANOVA with Tukey’s HSD post test (B and E), or log-rank test (C and D) are shown. See
also Figures S1 and S2.same machine-learning analysis in the spleen revealed no
changes in the clonality or diversity of the T cell repertoire with
either Gem/nP or aCD40 (data not shown). Therefore, aCD40
was independently associated with two significant changes in
the TCR repertoire specifically within the TME: expansion of
certain T cell clones and recruitment of new populations of rare
and small clones to the TME.
Functional Effector T Cells Require Both Gem/nP and
aCD40 Treatment
Although aCD40 independently mediated alterations in CD4+
and CD8+ T cell subsets, the addition of Gem/nP was required
for increased functionality of the T cell compartment and control
of tumor growth. CD4+ T cell production of IFN-g, TNF-a, and IL-
2 was significantly increased in Gem/nP/aCD40 treated tumorscompared to other groups (Figure 2G, left). Moreover, a higher
proportion of CD8+ T cells produced TNF-a or IFN-g, or both cy-
tokines, from tumors of mice treated with Gem/nP/aCD40
compared to Gem/nP or aCD40 alone (Figure 2G, right). Thus,
aCD40 significantly reduced the TReg population and enhanced
Th1 and Th17 subsets of CD4+ T cells, but the development of
functional effector CD4+ and CD8+ T cells was dependent on
the addition of Gem/nP to aCD40.
IFN-g Is Required for Gem/nP/aCD40 Efficacy
Given the increase in IFN-g production by both CD4+ and CD8+
T cells, we investigated the role of IFN-g in mediating Gem/nP/
aCD40-treatment induced immune responses to PDA. In IFN-g
knockout (KO) hosts bearing established tumors, response to
Gem/nP/aCD40 therapy at 24 days was fully abrogatedCell Reports 15, 2719–2732, June 21, 2016 2721
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(Figure 2H, left). Although vehicle-treated tumors grew some-
what faster in IFN-g KO mice versus wild-type mice, there was
no reduction in tumor growth rate when IFN-g KO mice were
treated with Gem/nP/aCD40 (Figure 2H, right). IFN-g is unlikely
to be derived from the natural killer cell compartment because
depletion with aNK1.1 did not alter tumor responses or growth
rates in Gem/nP/aCD40 treated mice (Figure S3). Additionally,
the intratumoral TReg compartment in IFN-g KO mice was not
significantly reduced after treatment with Gem/nP/aCD40 as it
is in wild-type mice, and consequently the CD8+ T cell:TReg ratio
was not skewed in favor of effector T cells (Figure 2I), indicating a
failure to generate effector T cells. The potent immune response
generated against PDA after Gem/nP/aCD40 was therefore
dependent on IFN-g for mediating tumor regressions and for
skewing the TME in favor of effector T cells.
Host CD40 Requirement and Increased Activation of
Antigen-Presenting Cells after Treatment with Gem/nP/
aCD40
To test the mechanism by which CD40-induced immunity is
potentiated by Gem/nP, we treated tumor-bearing CD40 KO
mice with Gem/nP/aCD40 therapy and observed no tumor re-
gressions or reduction in overall tumor growth rates (Figure 3A).
TReg reduction and skewing toward effector CD8 T cells at day 24
was also lost in the absence of host CD40 (Figure 3B). Because
CD40 KO hosts lack functional germinal center formation for the
generation of thymus-dependent B cell responses, we evaluated
whether the lack of Gem/nP/aCD40 efficacy in CD40 KO hosts
was due to a defect in the B cell compartment. We measured tu-
mor response rates and growth rates in mMTKOmice (which lack
mature B cells), but found thesewere similar to those in wild-type
mice (Figure 3C). Thus, host expression of CD40 is required for
the efficacy of Gem/nP/aCD40 therapy.
Following treatment with Gem/nP, tumor cell death increased
6 hr later (Figure S4) (Frese et al., 2012), suggesting potential
liberation of tumor antigens in vivo prior to aCD40. At 3 days
after chemotherapy administration (24 hr after aCD40), the pro-
portions of activated, MHCII+ CD86+ CD11b+ myeloid cells
in the TME were significantly increased in Gem/nP/aCD40
treated mice compared to other groups, including aCD40
alone (Figure 3D). This increase in activated populations was
also observed in CD11b+ F4/80+ macrophages and CD11bFigure 2. Gem/nP/aCD40 Therapy Alters T Cell Subsets, Repertoire, a
(A–D) Mice were treated as described in Figure 1A, and tumors were harvested 24
treatment, respectively) and analyzed by flow cytometry with regard to the proport
cells/gram of tumor (C) among live, CD45+ CD3+ cells.
(E and F) Tumorswere harvested on day 24 and analyzed by TCRdeep sequencing
cumulative frequencies of Rare (representing <105 total clones), Small (105 to <
to 1) clones within the total repertoire are indicated (E), or the repertoire diversity (
entire population (far left to middle right), or the Gini coefficient (0 indicating poly
(G) Tumors were harvested at day 24 and analyzed by flow cytometry with regard
cells.
(H) IFN-g KO mice were treated as described in Figure 1A. The change in tumor
(I) Tumors were analyzed on day 24 by flow cytometry with regard to the indicat
Each symbol represents an individual mouse, the horizontal lines indicate mean ±
each symbol represents a group with mean ± SEM. The data are representati
sequencing data, which is one experiment with 8–9mice/group. The statistical ana
and F), or two-way ANOVA (H) with Tukey’s HSD post test. See also Figure S3.CD11c+ dendritic cells (DCs) from Gem/nP/aCD40 treated
mice compared to Gem/nP or aCD40 alone (Figure 3D), and
was mostly lost by day 5 (72 hr after aCD40 administration)
(data not shown). The proportion of DCs,myeloid cells, andmac-
rophages producing IL-12 in Gem/nP/aCD40 treated mice were
also increased compared to Gem/nP or aCD40 alone (Figure 3E).
We observed a concomitant decrease in IL-10 production by
CD11b+ F4/80+ TAMs, CD11b+ Ly6C+ Ly6G+ myeloid derived
suppressor cells, and Ly6Chi CD11b+ inflammatory macro-
phages (Figure 3F). Thus, Gem/nP/aCD40 therapy uniquely
and significantly enhanced the activation status and function of
APCs and myeloid cells in the TME.
Batf3+ DCs Mediate Gem/nP/aCD40 Efficacy
To ascertain the role of APC subsets in mediating Gem/nP/
aCD40 tumor regression, we treated Batf3 KO mice (which
lack cross-presenting CD8a+ DCs) with Gem/nP/aCD40 and
observed no tumor regressions and a significant diminution in
overall tumor growth control (Figure 3G). We also targeted the
phagocytic and myeloid cell populations using seven indepen-
dent depletionmethods including clodronate-encapsulated lipo-
somes (Table S1), and although we observed a 30%–50%
reduction in the target cell populations in the TME, we were un-
able to detect any change in treatment efficacy (data not shown
and Winograd et al., 2015). Therefore, the effect of Gem/nP/
aCD40 therapy required cross-presentation of tumor antigens
by DCs for optimal immune responses against PDA.
Gem/nP/aCD40 Therapy Drives CD8+ T Cell-Mediated
Regression of Spontaneous PDA
Although 4662 subcutaneous tumors grow with extensive des-
moplastic stroma reminiscent of primary PDA (Lo et al., 2015),
we also studied Gem/nP/aCD40 treatment against autochtho-
nous tumors arising spontaneously in KPC mice. Mice were
enrolled after the diagnosis of a tumor (median volume
103 mm3, range 30–400 mm3) and treated with Gem/nP on day
0 and day 7 and aCD40 on day 2. Tumor-bearing KPC mice
treated with Gem/nP/aCD40 exhibited a 35.7% total response
rate, with tumor regressions in 3/14 mice and stable disease in
2/14 (Figure 4A). In comparison, KPC mice treated with vehicle
control, or with the combination of Gem/nP, had no regressions
or stabilization of disease, and only 1/14 mice treated withnd Function in PDA Tumors in an IFN-g-Dependent Manner
days (A–C) or 19 days (D) after tumor injection (12 and 7 days after initiation of
ion (A, B, and D) of the indicated subsets or the ratios of the absolute number of
. Mice are grouped based on receiving CD40 (top) or Gem/nP (bottom), and the
104), Medium (104 to < 103), Large (103 to < 102), or Hyperexpanded (102
‘‘true diversity,’’ indicating effective number of clones) for the top 10, top 20, or
clonal and 1 indicating monoclonal) on far right (F).
to the indicated parameters among CD4+ (left) or CD8+ (right) live, CD45+ CD3+
volume on day 24 (left) with growth kinetics (right) are shown.
ed subsets or ratios among live, CD45+ CD3+ cells.
SD (A–G and I) except for (H), where each bar represents a single mouse and
ve of 3–5 independent experiments with 4–6 mice/group, except TCR deep
lysis was performed by one-way ANOVA (A–D, G, and I), Mann-Whitney t test (E
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Figure 3. Gem/nP/aCD40 Therapy Requires Host CD40, Activates
Antigen-Presenting Cells, and Requires Batf3+ Dendritic Cells for
Efficacy
Mice were treated as described in Figure 1A.
(A and B) CD40 KO mice.
(A) Left, change in tumor volume on day 24 versus day 12 (start of therapy). The
tumor growth kinetics are shown on the right.
(B) Tumors were analyzed on day 24 with regard to the proportions of indicated
cells and ratios among live, CD45+ CD3+ cells.
2724 Cell Reports 15, 2719–2732, June 21, 2016aCD40 alone had stable disease at the 14-day time point after
the start of therapy (Figures 4A and 4B). The previously reported
30% rate of regressions to aCD40 observed in tumor-bearing
KPC mice (Beatty et al., 2011) was not observed here using
KPCmice that are fully C57BL/6 backcrossed, although a recent
report confirms the macrophage-dependency of aCD40 mono-
therapy in this strain of mice (Long et al., 2016). Moreover, in
contrast to the previously reported macrophage-dependent
(T cell-independent) regressions in KPC mice treated with
CD40 alone (Beatty et al., 2011), here, the response rate was
completely lost if mice treated with Gem/nP/aCD40 were first
depleted of CD8+ T cells (Figures 4A and 4B), indicating a shift
to a T cell-dependent immune response against spontaneous
PDA when combining both Gem and nP with aCD40.
CD8+ T cell infiltration of the spontaneous PDA TME was
significantly increased in KPC mice treated with Gem/nP/
aCD40 in comparison to Gem/nP or aCD40 alone (Figure 4C,
quantified on right). Additionally, the number of tertiary lymphoid
structures (a biomarker of increasingly appreciated immunolog-
ical importance, Dieu-Nosjean et al., 2014; Lutz et al., 2014) was
significantly increased in spontaneous PDA tumors after Gem/
nP/aCD40 (Figure 4D). The combination of Gem/nP/aCD40 ther-
apy therefore promotes the development of a robust and orches-
trated immune response within the primary tumor site, and al-
lows for CD8+ T cell infiltration and destruction of spontaneous
KPC tumors, a notoriously difficult site for adaptive immune cells
to penetrate.
Gem/nP/aCD40 Therapy Does Not Require Innate
Immune Sensors for Efficacy
Because aCD40 can synergize with TLR agonists (Ahonen et al.,
2008) and paclitaxel is an LPS mimetic (Ding et al., 1993), we
initially hypothesized that Gem/nP/aCD40 efficacy would require
TLR4 signaling. We were further attracted to this hypothesis
because of previous landmark studies reporting a critical role
of TLR4 for chemotherapy-induced anti-tumor immunity (Apetoh
et al., 2007). However, when TLR4 KO mice were treated with
Gem/nP/aCD40, tumor response rates and growth rates were
similar to wild-type mice (Figure 5A). Additionally, robust re-
sponses to Gem/nP/aCD40 were also observed in TRIF KO
and MyD88 KO mice, indicating that the downstream mediators
of TLR4 (aswell as all other TLRs) were not required for therapeu-
tic efficacy (Figures 5B and 5C). Caspase 11 (Casp 11) can also
function as an intracellular LPS receptor (Shi et al., 2014), but(C) mMT KOmice. The change in tumor volume on day 24 compared to day 12
is shown on the left. The tumor growth kinetics are shown on the right.
(D–F) Mice were treated as described in Figure 1A, and tumors were harvested
on day 15 (24 hr after receiving CD40) and analyzed by flow cytometry with
regards to the proportions of indicated subsets among live, CD45+ CD3 cells.
The CD11c+ cells are also CD11b F4/80.
(G) Batf3 KOmice treated as in Figure 1A. The change in tumor volume on day
24 versus day 12 is shown on the left, and the tumor growth kinetics are shown
on the right.
Each bar represents an individualmouse, the symbols indicate groups, and the
horizontal lines indicate mean ± SEM (A, C, and G) or each symbol represents
an individual mouse, with mean ± SD (B and D–F). Statistical analysis by one-
way ANOVA (B and D–F) or two-way ANOVA (A, C, and G) with Tukey’s HSD
post test is shown. See also Figure S4 and Table S1.
Gem/nP/aCD40 regressed PDA tumors in Casp 11 KO mice the
same as wild-type mice (Figure 5D).
Previous reports have shown that ATP released from dying tu-
mor cells stimulates DCs via ATP binding to P2X7R resulting in
Casp 1 activation and NLRP3 inflammasome assembly (Ghiring-
helli et al., 2009), but P2X7R KO mice bearing PDA tumors re-
sponded similarly to Gem/nP/aCD40 therapy as wild-type hosts
(Figure 5E). Additionally, we treated tumor-bearing IL-1R KO and
Casp 1/11 double KO hosts and found IL-1 signaling was
dispensable for treatment efficacy (data not shown). Therefore,
we found no role for the inflammasome pathways in mediating
the efficacy of Gem/nP/aCD40 therapy.
Previous studies have shown that MyD88/TLR4/P2X7R path-
ways are not obligatory for immune responses toward tumors
in every setting, but rather, the STING pathway can mediate
spontaneous or radiation-induced T cell responses against tu-
mors (Deng et al., 2014; Woo et al., 2014). However, STING
mutant (STING Mut) mice, which lack STING function, exhibited
tumor response rates and growth kinetics similar to wild-type
mice after Gem/nP/aCD40 therapy (Figure 5F). Moreover, Type
I IFNs (the downstream target of STING activation) were also
dispensable, as IFNAR KO hosts responded as well as wild-
type hosts to Gem/nP/aCD40 therapy (Figure 5G), despite the
role of Type I IFNs in aCD40/TLR agonist peptide vaccines (Aho-
nen et al., 2004). To exclude the possibility of cancer cell-auton-
omous signaling of Type I IFNs (Sistigu et al., 2014), we also
blocked IFNAR using anti-IFNAR1 mAb and found no reduction
in the efficacy of Gem/nP/aCD40 therapy (data not shown).
Therefore, we identified no role for STING or downstream Type
I IFNs in mediating responses to Gem/nP/aCD40 therapy. We
next investigated IL-12, using IL-12p40 or IL-12p35 KO mice,
as well as TNF-a, and found that treatment with Gem/nP/
aCD40 resulted in tumor responses and growth kinetics similar
to wild-type mice receiving therapy (Figure 5H and data not
shown).
Thus, Gem/nP/aCD40 treatment is mediated by CD40 and
IFN-g, but independent of 11 other signaling pathways and cyto-
kines, summarized in Table 1. These data illustrate the potency
of CD40 stimulation, in combination with Gem/nP, as a non-
redundant pathway with the capacity to override the need for
classically described innate sensors in mediating activation of
anti-tumor immune responses.
DISCUSSION
Although innate immune sensors can play critical roles in spon-
taneous and therapeutic tumor immunity, here, we demonstrate
that CD40 stimulation bypasses the need for TLRs, the inflam-
masome, Type I IFNs, and STING to generate effective priming
of adaptive T cell responses against cancer. Using a mutant
KRAS-driven mouse model of PDA, we observed that treatment
with an agonistic aCD40 mAb and chemotherapy alters multiple
dimensions of the cancer immunity cycle away from immuno-
suppression and toward T cell-dependent tumor rejection. The
ultimate effect is conversion of an otherwise immunologically
cold tumor into one with robust T cell infiltration. Mechanistically,
aCD40 and chemotherapy activated myeloid cells and drove
T cell function, but aCD40 was required to change T cell profilesin the TME and drive expansion of clonal effector T cell re-
sponses. Studies using KOmice showed that host CD40 expres-
sion is required for efficacy, as is IFN-g and cross-presenting
DCs. Thus, both gain-of-function and loss-of-function studies
highlight the non-redundant role of CD40 activation, in combina-
tion with Gem/nP, to obviate the need of innate immune sensing
for durable anti-cancer T cell immunity.
In contrast to immune checkpoint antibodies that unlock pre-
existing T cell immunity against cancer, our data support the
notion of aCD40 mAb as a complimentary therapeutic strategy
in which immune cells are directly activated using an agonistic
mAb (rather than blocking mAb) to achieve T cell priming. Ex-
pressed by APCs, CD40 uniquely sits proximal in the T cell acti-
vation cascade compared to other activation receptors, such as
OX40, GITR, or CD137, the ligands of which are upregulated by
CD40 activation (Summers deLuca and Gommerman, 2012). To
exploit this pathway pharmaceutically, a number of agonistic
CD40 antibodies are being evaluated in cancer clinical trials (Me-
lero et al., 2013; Vonderheide and Glennie, 2013). Our group has
shown that one such CD40 mAb (CP-870,893) results in modest
rates of objective tumor regression as a single agent in patients
with melanoma (Bajor et al., 2014; Vonderheide et al., 2007) in
the absence of autoimmune-like events associated with aPD-1
or aCTLA-4 therapy. Nevertheless, studies from tumor-bearing
mice predict that aCD40 alone in the absence of a ‘‘vaccine’’
to deliver tumor antigen will be an inefficient therapeutic
approach. Indeed, T cell-mediated tumor regressions with
aCD40 alone in mice have largely been reported only in immuno-
genic tumors such as those expressing viral antigens (van Mierlo
et al., 2002).
We therefore examined the therapeutic prospect of aCD40 as
an immune combination partner in our PDA models with a new
standard-of-care Gem/nP chemotherapy. Although the addition
of Gem to aCD40 was found to enable T cell immunity against
murine mesothelioma (Nowak et al., 2003), in our model of
PDA, Gem/aCD40 (without nP) mediates potent T cell immunity
against subcutaneous tumors, but not in spontaneous KPC tu-
mors for which the T cell response is restrained bymacrophages
(Beatty et al., 2011, 2015). Accordingly, Gem/aCD40 therapy
resulted in modest tumor regression rates in patients with meta-
static PDA, but tumors lacked T cell infiltrates, and all patients
eventually progressed (Beatty et al., 2011). Here, using the
chemotherapy doublet of Gem/nP, we observed clear evidence
of T cell-mediated regression in both subcutaneous and sponta-
neous KPC tumors, suggesting an immunological benefit of
Gem/nP compared to Gem alone. Probing the immunological
mechanism underlying Gem/nP/CD40 efficacy, we found that
chemotherapy and aCD40 therapy shifted the myeloid compart-
ment toward an M1 bias, and the T cell subsets toward a Th1
bias, in terms of both phenotype and function, with a near com-
plete collapse of the intratumoral TReg compartment. Impor-
tantly, based on TCR deep sequencing of intratumoral T cells,
treatment with aCD40 was independently associated with
expansion of the top clones within TCR repertoire, as well as
the recruitment of new clones to the TME.
Taken together, our findings support a mechanistic model of
tumor immunity in which the addition of both Gem and nP con-
verts the effect ofaCD40 therapy frommacrophage-dependencyCell Reports 15, 2719–2732, June 21, 2016 2725
Figure 4. Spontaneous Tumors in KPC Mice Respond to Gem/nP/aCD40 Therapy in T Cell-Dependent Fashion
KPCmice diagnosed with established tumors received Gem/nP on day 0 and day 7 and aCD40was given on day 2. Somemice (as indicated) also received aCD8
depletion for the duration of enrollment.
(legend continued on next page)
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Figure 5. Gem/nP/aCD40 Therapy Bypasses Innate Immune Sensors for Treatment Efficacy
Mice were treated as outlined in Figure 1A, and for each panel: left, change in tumor volume on day 24 compared to day 12 (start of therapy), right, tumor growth
kinetics.
(A–H) TLR4 KO (A), MyD88 KO (B), TRIF KO (C), Casp 11 KO (D), P2X7R KO (E), STING Mut (F), IFNAR KO (G), and IL-12p40 KO (H).
Each bar represents a single mouse, each symbol represents a group with error bars indicating mean ± SEM, and the data show representatives of 2–5 inde-
pendent experiments for each KO strain with 4–10 mice per group. The statistical analysis was by two-way ANOVA with Tukey’s HSD post test.to T cell-dependency. The combination chemotherapy fuels tu-
mor antigen release that cooperates with CD40-mediated DC
activation and drives T cell priming. nP, but not Gem, increased
tumor cell death shortly after administration so that aCD40 given
2days later optimally impacts antigen-loadedDCs.Moreover, ef-
ficacy of Gem/nP/aCD40 was lost in Batf3 KO mice, which lack
DCs most capable of antigen cross-presentation. Thus, insuffi-
cient APC activation and antigen presentation—an important
immune deficiency in cancer—may be uniquely addressed via
aCD40 therapy.(A) The change in tumor volume on day 14 compared to initial tumor volume at d
(B) Tumor growth curves for indicated groups, responders indicated in red.
(C) Representative histological samples from (A) at day 14, stained for CD8, shown
right. The scale bar represents 200 mm (top) or 300 mm (bottom).
(D) Representative H&E samples of tumors from (A) at day 14 shown on left, quanti
arrowheads (23) point to TLS (top), the asterisk indicates a tumor-associated ly
resents 1,000 mm (top) or 100 mm (bottom).
Each bar, line, or symbol represents an individual mouse and the horizontal lines
HSD post test (C and D) and Fisher’s exact test (A) are shown.Given the immune benefit from the addition of Gem/nP, it is
interesting that classical innate immune sensing—as evaluated
in vivo both genetically and pharmacologically—played no role
in mediating T cell regression triggered by Gem/nP/aCD40.
There were 11 such pathways—including MyD88, P2X7R, and
IFNAR—that were tested, but none was found to be required.
In certain previous studies, chemotherapy alone induces immu-
nogenic tumor cell death dependent on host MyD88/TLR4
signaling (Apetoh et al., 2007). In other experimental models,
response to chemotherapy is independent of the adaptiveiagnosis, responders calculated in table below.
on left at twomagnifications, quantification of global CD8 staining in tumors on
fication of tertiary lymphoid structures (TLS) in entire tumor section on right. The
mph node, and the outline indicates the field below (203). The scale bar rep-
indicate mean ± SD. The statistical analysis by one-way ANOVA with Tukey’s
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Table 1. Gem/nP/aCD40 Is Dependent Only on Host CD40 and
IFN-g, T Cells, and Batf3+ DCs
Target Response to Gem/nP/aCD40
Signaling Molecules
CD40 No
MyD88 Yes
TLR4 Yes
TRIF Yes
TLR3 Yes
Caspase 1 Yes
Caspase 11 Yes
STING Yes
P2X7R Yes
Cytokines
IFN-g No
IFN-a/b Yes
IL-1 Yes
IL-12 Yes
TNF-a Yes
Adaptive Immune Cells
CD4+ T cells No
CD8+ T cells No
B cells Yes
Innate Immune Cells
Batf3+ DCs No
NK cells Yes
Proteins or cells required for therapeutic efficacy are italic.immune system, particularly in spontaneous mouse tumor
models (Ciampricotti et al., 2012), and may require additional
modifiers of the TME to trigger T cell responses, e.g., inhibition
of CSF-1R (DeNardo et al., 2011; Zhu et al., 2014) or BTK
(Masso´-Valle´s et al., 2015).
Our approach with aCD40 is therapeutically and mechanisti-
cally distinct from other strategies to enhance T cell immunity
against PDA, offering the potential for further synergistic combi-
nations. For example, FAP+ stromal cells in PDA regulate T cell
infiltration to PDA via CXCL12/CXCR4 (Feig et al., 2013), but
FAP+ stromal cells in the KPC model are CD40-negative, and
FAP+ cell depletion (or CXCR4 inhibition) does not negatively
impact TRegs in the way aCD40/chemotherapy does in the
same KPC model. Vaccination with recombinant antigen-ex-
pressing Listeria is another powerful method to generate anti-
PDA T cells (Keenan et al., 2014), but appears to rely on STING
activation (Jin et al., 2013; Woodward et al., 2010), unlike
aCD40. Other treatments that can mediate T cell responses
against PDA include GVAX vaccination (Le et al., 2015; Soares
et al., 2015), adoptive transfer of antigen-receptor engineered
T cells (Stromnes et al., 2015), and CSF-1R inhibition (Zhu
et al., 2014). Although antibody blockade of PD-1 (or PD-L1)
with or without aCTLA-4 is largely ineffective in treating PDA in
mice or patients (Brahmer et al., 2012; Herbst et al., 2014; Twy-
man-Saint Victor et al., 2015; Winograd et al., 2015; Zhu et al.,
2014), PD-1 blockade in mice synergizes with certain T cell ther-2728 Cell Reports 15, 2719–2732, June 21, 2016apies in PDA (Feig et al., 2013; Le et al., 2015; Soares et al., 2015;
Zhu et al., 2014). Indeed, we have shown that the addition of
checkpoint blockade to Gem/nP/aCD40 in tumor-bearing mice
enhances survival in both implantable and spontaneous PDA
models (Winograd et al., 2015), and here we show the mecha-
nism by which the PDA TME is rendered sensitive to PD-1 and
CTLA-4 antibodies used in that study. Taken together, these re-
ports highlightmultiple immune vulnerabilities of PDA that can be
targeted in a non-redundant fashion in combination with aCD40
in clinical trials (Melero et al., 2013).
Although the T cells generated by Gem/nP/aCD40 mediate
tumor regressions and long-term protection, the precise anti-
gens targeted by this response remain unknown. The minimal
expression of non-synonymous mutations in our KPC model
and the lack of predicted neo-epitopes able to bind MHC class
I (n = 0–5 predicted neo-epitopes per tumor; unpublished data)
suggests the target peptide-MHC tumor repertoire is mecha-
nistically distinct from that underlying responsiveness to check-
point blockade. Human PDA also exhibits a scarcity of non-
synonymous mutations such that the burden of neo-epitopes
may be relatively low compared to carcinogen-induced tumors
such as lung carcinoma or melanoma (Alexandrov et al., 2013;
Gubin and Schreiber, 2015; Jones et al., 2008; Sausen et al.,
2015). Although peptides derived from mutated KRAS can
potentially function as tumor-specific antigens (Tran et al.,
2015), vaccination against mutated KRAS is unable to slow
growth of established PDA tumors (Keenan et al., 2014). It is
possible that T cells generated after Gem/nP/aCD40 treatment
are specific for self-antigens, but we did not observe autoim-
munity or related toxicities in our experiments, suggesting
that these potential antigens are not strongly expressed on
essential tissues. Given the shared protection between two in-
dependent KPC-derived PDA cell lines, our findings justify a
reconsideration of self-antigens—as well as ‘‘abnormal self-an-
tigens’’ not derived on the basis of non-synonymous mutations
(Cobbold et al., 2013; Ryan et al., 2010)—as potential tumor
rejection antigens.
In summary, our findings demonstrate the powerful ability of
a single dose of aCD40 to alter T cells in the TME, expand
clonal T cell populations, and convert the TME in pancreatic
cancer to a site replete with infiltrating T cells. In combination
with a novel chemotherapy doublet, aCD40 treatment by-
passes innate immune sensors to generate functional
APCs and T cells, culminating in durable responses with cura-
tive potential, even in a highly immunosuppressive TME. With
the goal of rapidly translating these observations to patients,
a newly opened clinical trial (http://www.clinicaltrials.gov,
#NCT02588443) is evaluating the administration of Gem/nP
and aCD40 before and after surgery in patients presenting
with resectable PDA.
EXPERIMENTAL PROCEDURES
Mice
KPC mice have been previously described (Hingorani et al., 2005) and were
bred and maintained in the specific pathogen-free facility at the University of
Pennsylvania. The genetic background of the C57BL/6 KPC mice was as-
sessed at the DartMouse Speed Congenic Core Facility at the Geisel School
of Medicine at Dartmouth College, as described in the Supplemental
Information. STING Mut (Tmem173gt/J) (Sauer et al., 2011) were kindly pro-
vided by Dr. Susan Ross (Perelman School of Medicine, University of Pennsyl-
vania). All wild-type C57BL/6 and other KO mice (Supplemental Information)
were purchased from The Jackson Laboratory and/or bred at the University
of Pennsylvania. Most experiments with wild-type C57BL/6 mice were per-
formed in female mice, but tumor growth responses were confirmed in male
mice. Experiments in KO and KPC mice were performed with mixed gender
mice distributed across treatment groups. Animal protocols were reviewed
and approved by the Institute of Animal Care and Use Committee at the Uni-
versity of Pennsylvania.
Cell Lines and In Vivo Growth
Themouse pancreatic cancer cell line 4662was previously described (Lo et al.,
2015). PDA cells were used in experiments after 3–5 passages in vitro;
C57BL/6 mice received 2.5 3 105 PDA cells subcutaneously only if tumor
cell viability was >94%. Cell lines were tested by using the Infectious Microbe
PCR Amplification Test (IMPACT) and authenticated by the Research Animal
Diagnostic Laboratory (RADIL) at the University of Missouri. Tumors
were measured thrice weekly by calipers, and the volume was calculated by
(L 3W2)/2, where L is the longest diameter and W is the perpendicular diam-
eter. Mice were designated as responders if tumors had regressed 12–14 days
after the initiation of treatment.
Drug Preparation
Gem (Hospira) pharmaceutical grade suspension at 38mg/ml 20-deoxy-20,20-di-
fluorocytidinewasdiluted to12mg/ml inPBSandadministeredat 120mg/kg via
intraperitoneal (i.p.) injection (Beatty et al., 2011). nP (Abraxane, Celgene) phar-
maceutical grade powder was resuspended at 12 mg/ml in PBS and adminis-
tered at 120 mg/kg i.p. (Frese et al., 2012) or equivalent molar dose of human
albumin (huAlb) (Sigma).Gem/nPor huAlbwas injected onday12 after tumor in-
jection in subcutaneous PDA experiments and on days 0 and 7 in KPC mice.
Gem and nP were purchased through the Hospital of the University of Pennsyl-
vania Pharmacy.
Monoclonal Antibodies
Mice received 100 mg of either agonist CD40 rat anti-mouse IgG2a mAb (clone
FGK45, endotoxin-free), or the isotype control IgG2a mAb (clone 2A3) (Beatty
et al., 2011) on day 14 after 4662 injection or day 2 in KPCmice. CD4+ or CD8+
T cells were depleted with 200 mg each of clone GK1.5 or clone 2.43, respec-
tively, injected i.p. on day 10 and repeated every 4 days, or IgG2b isotype con-
trol (clone LTF-2). CD4+ and CD8+ T cell depletion was confirmed by staining
peripheral blood (data not shown). KPCmice received CD8 depleting antibody
starting on day 1 and repeated every 4 days until day 14. All antibodies were
purchased from BioXCell.
Tumor Regression Studies in KPC Mice
KPC mice were monitored for spontaneous tumors by ultrasonography every
1–2 weeks using the Vevo 2100 Imaging System with 55 MHz MicroScan
Transducer from Visual Sonics. Mice with tumors measuring at least 30 mm3
were enrolled within 24 hr of baseline imaging using blocked randomization
to assign treatment group. Mice were designated as responders if disease
was stable (progression <20% compared to baseline) or if tumors regressed
14 days after initiation of treatment.
Preparation of Tissue Samples from Mice
Mice were euthanized either on day 15, 19, 24, or 26 after 4662 injection, and
tumors, draining lymph nodes, and spleens were harvested, as indicated. Tu-
mors were minced and incubated for 45 min in 1 mg/ml collagenase V in
DMEM at 37C. Tumors, spleen, and lymph nodes were mechanically dissoci-
ated and passed through a 70 mM cell strainer, spleens were incubated in ACK
lysis buffer (BioWhittaker), and then tissueswere used for flow cytometric anal-
ysis as single cell suspensions. Cells were counted using the Beckman Coulter
Counter Z2.
Flow Cytometry
Cell surface molecules were analyzed by incubating single cell suspensions of
tissues with primary fluorochrome-labeled antibodies at 4C for 30 min in PBSwith 0.5% BSA and 2 mM EDTA. For cytokine production by T cell subsets,
samples were incubated for 4–5 hr at 37C with PMA/ionomycin (Sigma) and
Brefeldin A (Sigma). Intracellular staining was done using the Fixation/Perme-
abilization Kit from eBiosciences. For cytokine production by APCs and
myeloid cells, samples were incubated for 4–5 hr with Brefeldin A and Golgi-
stop (BD Biosciences), with 1 mg/ml LPS (Sigma). Antibodies used in flow anal-
ysis are described in the Supplemental Information. Flow cytometric analysis
was performed on a FACSCanto or LSR II Flow Cytometer (BD Biosciences).
Collected data were analyzed using FlowJo software (Treestar).
Immunohistochemistry
Tumors were embedded in optimal cutting temperature compound (OCT) and
then sectioned in 5 mm slices, fixed in acetone, and stained using a Bond Max
automatedstainingsystem (LeicaMicrosystems),with theBond IntenseRstain-
ingkit (LeicaMicrosystems), usingCD8primaryantibody (clone53-6.7,Abcam).
H&Estainswereperformedaccording tomanufacturer’sdirections (Sigma). The
histopathological scoring is detailed in the Supplemental Information.
TCR Deep Sequencing and Analysis
High-throughput next-generation sequencing of the TCR-b CDR3 region was
performed by Adaptive Biotechnologies using the ImmunoSeq platform (Sup-
plemental Information). Analysis of TCR-b repertoire was performed using the
tcR Rpackage (Nazarov et al., 2015). Random forest machine learning for clas-
sification predictions was performed using the randomForestSRC R package
(Ishwaran and Kogalur, 2010) as previously described (Twyman-Saint Victor
et al., 2015).
Statistical Analyses
Significance of overall survival was determined using Kaplan-Meier survival
curve with log-rank analysis. All other comparisons were performed using
one- or two-way ANOVA with Tukey’s HSD post test, or Mann-Whitney t
test, as indicated. All statistical analyses were performedwith Graphpad Prism
6 (GraphPad). SD or SEM shown as indicated by error bars. p < 0.05 was
considered statistically significant; *p < 0.05, ** p < 0.01, *** p < 0.001, and
*** p < 0.0001 and ns (or lack of indicated p value) denotes not significant
(p > 0.05).
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
four figures, and one table and can be found with this article online at http://
dx.doi.org/10.1016/j.celrep.2016.05.058.
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